Advaxis – pharmaceutical daily

April 2, 2019 Off

Advaxis, Inc. Announces Proposed Public Offering of Common Stock

PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of…

March 28, 2019 Off

Advaxis Announces Reverse Stock Split

By BusinessWire

PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced…

May 30, 2017 Off

Advaxis, BMS combining drugs to treat cervical cancer

By Dino Mustafić

Advaxis and Bristol-Myers Squibb have announced a clinical development collaboration to evaluate ADXS-DUAL, an investigational immunotherapy targeting HPV-associated cancers, and Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), as a potential combination treatment option for women with metastatic cervical cancer.

November 17, 2015 Off

Advaxis to get $1.6M through New Jersey Technology Business Tax (NOL) Program

By Dino Mustafić

Advaxis, a clinical-stage biotechnology company developing cancer immunotherapies, has received preliminary approval for a $1.8 million tax credit from the New Jersey Technology Business Tax Certificate Transfer (NOL) Program for the year 2015.